Cargando…
Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
Prediction of treatment response is a crucial issue in individualised treatment for cancer patients. In this context, Nassar and colleagues in the accompanying study published in the British Journal of Cancer analysed retrospectively a cohort of 62 metastatic urothelial cancer patients treated with...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029037/ https://www.ncbi.nlm.nih.gov/pubmed/31857721 http://dx.doi.org/10.1038/s41416-019-0684-2 |
_version_ | 1783499087303147520 |
---|---|
author | Niegisch, Günter |
author_facet | Niegisch, Günter |
author_sort | Niegisch, Günter |
collection | PubMed |
description | Prediction of treatment response is a crucial issue in individualised treatment for cancer patients. In this context, Nassar and colleagues in the accompanying study published in the British Journal of Cancer analysed retrospectively a cohort of 62 metastatic urothelial cancer patients treated with immune checkpoint inhibitors and of whom not only clinical but also genomic characteristics were available. Combining molecular and clinical factors in a multivariable analysis they identified lack of visceral metastases, neutrophil-to-lymphocyte ratio (NLR) <5, and high single nucleotide variant (SNV) count (≥10) as independent predictors of treatment response. |
format | Online Article Text |
id | pubmed-7029037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70290372020-12-20 Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? Niegisch, Günter Br J Cancer Editorial Prediction of treatment response is a crucial issue in individualised treatment for cancer patients. In this context, Nassar and colleagues in the accompanying study published in the British Journal of Cancer analysed retrospectively a cohort of 62 metastatic urothelial cancer patients treated with immune checkpoint inhibitors and of whom not only clinical but also genomic characteristics were available. Combining molecular and clinical factors in a multivariable analysis they identified lack of visceral metastases, neutrophil-to-lymphocyte ratio (NLR) <5, and high single nucleotide variant (SNV) count (≥10) as independent predictors of treatment response. Nature Publishing Group UK 2019-12-20 2020-02-18 /pmc/articles/PMC7029037/ /pubmed/31857721 http://dx.doi.org/10.1038/s41416-019-0684-2 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Editorial Niegisch, Günter Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? |
title | Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? |
title_full | Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? |
title_fullStr | Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? |
title_full_unstemmed | Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? |
title_short | Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? |
title_sort | predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029037/ https://www.ncbi.nlm.nih.gov/pubmed/31857721 http://dx.doi.org/10.1038/s41416-019-0684-2 |
work_keys_str_mv | AT niegischgunter predictingimmunecheckpointinhibitorresponseinurothelialcarcinomaanotherstepinpersonalisedmedicine |